| 1 |
35617514 | Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B). | 2022 May 26 |
1 |
| 2 |
33574724 | Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling. | 2021 |
1 |
| 3 |
33664875 | Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. | 2021 |
1 |
| 4 |
34575554 | Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. | 2021 Sep 15 |
1 |
| 5 |
34885115 | The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. | 2021 Nov 29 |
4 |
| 6 |
31821539 | ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. | 2020 Mar 15 |
4 |
| 7 |
32497272 | MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. | 2020 Aug 15 |
2 |
| 8 |
30831205 | Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. | 2019 May |
2 |
| 9 |
29641535 | Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. | 2018 |
1 |
| 10 |
28765329 | Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. | 2017 Nov 1 |
8 |
| 11 |
25870145 | Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. | 2015 Jun 15 |
1 |